Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Oculis Holding AG (OCS)

Gyre Therapeutics, Inc. and Oculis Holding AG are both Biotechnology companies. Gyre Therapeutics, Inc. and Oculis Holding AG are of similar size ($425.2M and $421.6M). Oculis Holding AG grew revenue faster over the last twelve months: 25.0% against 13.5%. Gyre Therapeutics, Inc. has the higher net margin (−21.5% vs −8,709.4%) and the higher return on invested capital (−8.51% vs −12,858.7%). Across the 17 metrics below, Gyre Therapeutics, Inc. leads on 12 and Oculis Holding AG on 5.

Valuation

Metric GYRE OCS Biotechnology median
P/E n/m n/m 10.60
P/S 4.12 393.17 9.40
P/B 3.47 1.80 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3.55 175.67 9.02
Earnings yield (5.93%) (23.24%) (32.88%)
Free cash flow yield (5.07%) (18.69%) (23.13%)

Profitability

Metric GYRE OCS Biotechnology median
Gross margin 91.71% 100.00% 68.51%
Operating margin 0.00% (9,551.41%) 0.00%
Net margin (21.46%) (8,709.42%) 0.00%
Free cash flow margin (19.94%) (7,237.57%) 0.00%
Return on equity (18.54%) (48.81%) (51.96%)
Return on assets (14.49%) (41.38%) (46.06%)
Return on invested capital (8.51%) (12,858.67%) 0.00%

Growth

Metric GYRE OCS Biotechnology median
Revenue growth (TTM) 13.51% 25.01% 6.76%
EPS growth (last fiscal year) (60.00%) 5.39% 29.88%
Revenue growth, 5-year CAGR 40.96% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GYRE OCS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 4.32 10.41 4.97
Net debt to EBITDA (3.74) 2.60 1.01

Dividend

Metric GYRE OCS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GYRE OCS Biotechnology median
Market cap 425.20m 421.63m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack